PANACEABIO

Panacea Biotec Share Price

₹507.55 -9.25 (-1.79%)

21 May, 2025 20:03

SIP TrendupStart SIP in PANACEABIO

Start SIP

Performance

  • Low
  • ₹501
  • High
  • ₹523
  • 52 Week Low
  • ₹112
  • 52 Week High
  • ₹582
  • Open Price₹517
  • Previous Close₹517
  • Volume142,753

Investment Returns

  • Over 1 Month -2.94%
  • Over 3 Month + 48.65%
  • Over 6 Month + 28.72%
  • Over 1 Year + 268.19%
SIP Lightning

Smart Investing Starts Here Start SIP with Panacea Biotec for Steady Growth!

Invest Now

Panacea Biotec Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -393
  • PEG Ratio
  • -11.2
  • Market Cap Cr
  • 3,109
  • P/B Ratio
  • 3.7
  • Average True Range
  • 27.63
  • EPS
  • 0
  • Dividend Yield
  • 0
  • MACD Signal
  • 19.6
  • RSI
  • 49.61
  • MFI
  • 45.27

Panacea Biotec Financials

Panacea Biotec Technicals

EMA & SMA

Current Price
₹507.55
-9.25 (-1.79%)
pointer
  • stock-down_img
  • Bearish Moving Average 9
  • stock-up_img
  • Bullish Moving Average 7
  • 20 Day
  • ₹517.87
  • 50 Day
  • ₹480.86
  • 100 Day
  • ₹439.09
  • 200 Day
  • ₹377.13

Resistance and Support

510.7 Pivot Speed
  • R3 542.65
  • R2 533.05
  • R1 520.30
  • S1 497.95
  • S2 488.35
  • S3 475.60

What's your outlook on Panacea Biotec?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Panacea Biotec is a biotechnology company specializing in research, development, and manufacturing of vaccines, pharmaceuticals, and biosimilars. It operates state-of-the-art facilities in India, serving global markets across North America, Europe, and emerging economies.

Panacea Biotec (Nse) has an operating revenue of Rs. 563.02 Cr. on a trailing 12-month basis. An annual revenue growth of 14% is good, Pre-tax margin of 0% needs improvement, ROE of -0% is poor and needs improvement. The company has a reasonable debt to equity of 2%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 14% and 44% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 5% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 65 which is a FAIR score but needs to improve its earnings, a RS Rating of 97 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 82 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Panacea Biotec Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-02-14 Quarterly Results
2024-11-13 Quarterly Results
2024-08-14 Quarterly Results
2024-05-30 Audited Results
2024-02-13 Quarterly Results

Panacea Biotec F&O

Panacea Biotec Shareholding Pattern

72.48%
0%
1.16%
18.45%
7.91%

About Panacea Biotec

  • NSE Symbol
  • PANACEABIO
  • BSE Symbol
  • 531349
  • Chairman & Managing Director
  • Dr. Rajesh Jain
  • ISIN
  • INE922B01023

Similar Stocks to Panacea Biotec

Panacea Biotec FAQs

Panacea Biotec share price is ₹507 As on 21 May, 2025 | 19:49

The Market Cap of Panacea Biotec is ₹3108.8 Cr As on 21 May, 2025 | 19:49

The P/E ratio of Panacea Biotec is -393 As on 21 May, 2025 | 19:49

The PB ratio of Panacea Biotec is 3.7 As on 21 May, 2025 | 19:49

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23